Oppenheimer analyst Justin Kim raised the firm’s price target on Vera Therapeutics to $34 from $26 and keeps an Outperform rating on the shares. The firm was struck by the more definitive clinician perspectives on APRIL(/BAFF) B cell modulatory approaches in IgAN, following 72-week results, the analyst tells investors in a research note. Vera’s updates highlighted a consistency of results demonstrated at 72-weeks, particularly with a stabilization observed among placebo patients converted to open-label atacicept drug.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERA:
- Vera Therapeutics Reports Positive Phase 2b ORIGIN Trial Results
- Vera Therapeutics Announces Promising 72-Week Trial Results
- Vera Therapeutics’ atacicept shows positive Phase 2b data in IgA nephropathy
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
- Vera Therapeutics to host research and development day
